AbbVie invests €150m in new R&D facility in Germany
Betsy Goodfellow | May 3, 2024 | News story | Research and Development | AbbVie, Pharmacy, R&D, facility
AbbVie has announced that it is investing approximately €150m in its second largest research and development (R&D) facility worldwide. The new facility is being built at Ludwigshafen, Germany.
It is expected that the facility will be home to a state-of-the-art research and laboratory building, and will employ over 300 researchers and scientists. AbbVie has shared that the facility is being built with modern and sustainable infrastructure features, thus allowing for flexible working conditions in an attempt to enable greater scientific exchange between different areas of the business.
Martin Gastens, vice president of biologics and drug product development and managing director of R&D at AbbVie Germany, commented: “For AbbVie Germany, the new construction of our ‘LUnA’ research building is much more than a €150m investment in cutting-edge infrastructure. It is a promise for the future of AbbVie science and innovation. We are creating attractive working conditions for our top scientists and attracting new talent so that we can conduct cutting-edge research at our site in the long term […] We are very pleased that the Federal Government has taken action with the pharmaceutical strategy and has begun to make Germany a pharmaceutical location fit for the future. After all, the political framework is critical for future investment decisions.”
Rhineland Palatinate’s minister president, Malu Dreyer, added: “The German state of Rhineland-Palatinate is on track to become one of the leading hubs for biotechnology and life sciences. We support research, promote its translation and continue expanding the footprint. As the Government of the Federal State of Rhineland-Palatinate, we are proud of this additional investment made by AbbVie, and the trust which yet another large pharmaceutical company has placed in our state. We are working tirelessly on creating the best possible framework conditions for business and research, and are collaborating closely in a network with all those involved through the biotechnology advisory board and the biotechnology academy. We are actively encouraging companies to put down roots and to invest in our Federal State, and once again I’d like to express my heartfelt thanks to AbbVie for the excellent collaboration, the sharing of experiences and the great investment.”
Betsy Goodfellow
Related Content
Eli Lilly acquires new manufacturing facility from Nexus Pharmaceuticals
Eli Lilly and Nexus Pharmaceuticals have announced that they have entered into a definitive agreement …
Ardena announces €20m expansion following first GMP approval
Ardena has announced that it has received Good Manufacturing Practice (GMP) approval from the Dutch …
Medincell and AbbVie enter agreement for development of next-generation injectables
Medincell and AbbVie have announced that they have entered into a collaboration to co-develop and …
